Browse by author
Lookup NU author(s): Dr Lesley Kay
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Objectives. Anti-tumour necrosis factor (anti-TNF) therapy is a highly effective treatment for rheumatoid arthritis (RA), as documented using standard outcome measures in clinical trials. Anecdotal experience suggests health benefits for patients other than those measured in this way. We wished to explore Patients' experience of and views about this treatment and the British Society for Rheumatology Biologics Registry (BSR BR) process. Methods. Separate focus groups for patients treated with infliximab (n = 7) and etanercept (n = 12) were undertaken. They were taped and transcribed verbatim, analysed and subjected to peer review and themes were identified. Results. Five main themes were identified: expectations of treatment, experience of treatment and its effects, concerns about taking a new class of drug, views about the BSR Biologics Registry process and costs. Conclusions. Patients' experience of anti-TNF therapy was good, particularly in terms of physical function and well-being, although it did not live up to the very high expectations of some patients. The BSR BR process caused initial apprehension but patients had personal and altruistic reasons for being happy to comply with monitoring requirements. Qualitative methods add to our understanding of the effects of anti-TNF therapy for people with RA.
Author(s): Marshall NJ, Wilson G, Lapworth K, Kay LJ
Publication type: Article
Publication status: Published
Journal: Rheumatology
Year: 2004
Volume: 43
Issue: 8
Pages: 1034-1038
ISSN (print): 1462-0324
ISSN (electronic): 1462-0332
Publisher: Oxford University Press
URL: http://dx.doi.org/10.1093/rheumatology/keh237
DOI: 10.1093/rheumatology/keh237
Altmetrics provided by Altmetric
